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Abstract
Background—The objectives of this study were to evaluate the quality of national data 
generated by the National Breast and Cervical Cancer Early Detection Program (NBCCEDP); to 
assess variables collected through the program that are appropriate to use for program 
management, evaluation, and data analysis; and to identify potential data-quality issues.
Methods—Information was abstracted randomly from 5603 medical records selected from 6 
NBCCEDP-funded state programs, and 76 categorical variables and 11 text-based breast and 
cervical cancer screening and diagnostic variables were collected. Concordance was estimated 
between abstracted data and the data collected by the NBCCEDP. Overall and outcome-specific 
concordance was calculated for each of the key variables. Four screening performance measures 
also were estimated by comparing the program data with the abstracted data.
Results—Basic measures of program outcomes, such as the percentage of women with cancer or 
with abnormal screening tests, had a high concordance rate. Variables with poor or inconsistent 
concordance included reported breast symptoms, receipt of fine-needle aspiration, and receipt of 
colposcopy with biopsy.
Conclusions—The overall conclusion from this comprehensive validation project of the 
NBCCEDP is that, with few exceptions, the data collected from individual program sites and 
reported to the CDC are valid and consistent with sociodemographic and clinical data within 
medical records.
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The Breast and Cervical Cancer Mortality Act passed by Congress in 1990 guided the 
Centers for Disease Control and Prevention (CDC) in establishing the National Breast and 
Cervical Cancer Early Detection Program (NBCCEDP).1 This legislation authorized the 
CDC to establish the first national federally supported program to increase access to and use 
of breast and cervical cancer screening and diagnostic services for low-income women who 
are uninsured or underinsured. The NBCCEDP is administered through cooperative 
agreements with state and territorial health departments, tribes, and tribal organizations. This 
program currently funds all 50 states, the District of Columbia, 5 US territories, and 12 
American Indian and Alaska Native tribes or tribal organizations. Since their inception in 
1991, NBCCEDP-funded programs have screened over 4.5 million women and have 
diagnosed 62,121 breast cancers, 3458 invasive cervical cancers, and 163,548 premalignant 
cervical lesions (available at: http://www.cdc.gov/cancer/nbccedp/about.htm; Accessed May 
28, 2014).
To monitor and assess program performance, all NBCCEDP programs are required to 
submit surveillance data to the CDC for women who received services within the program. 
Clinical services are provided to eligible women through program-established networks of 
more than 22,000 providers across different settings. Programs collect clinical data from 
these providers through a variety of systems and standardize the data to report to the CDC. 
These data, referred to as the Minimum Data Elements (MDEs), provide valuable 
information for understanding who uses the program and for assuring the provision of 
complete and timely service for women screened. The CDC reviews the MDEs regularly to 
monitor and evaluate the program; to report results to Congress, program partners, and the 
public; and to analyze the data for publication in reports and professional journals.2-8 
Although data are routinely assessed at the program level, we conducted a supplemental 
evaluation of data quality to assess the accuracy of the NBCCEDP MDE data maintained by 
the CDC. For a sample of records, we abstracted clinical information directly from the 
medical records and compared those data with the information submitted to the CDC in the 
MDEs by NBCCEDP-funded programs.
Materials and Methods
Procedures for protecting human subjects were completed at the CDC as well as within the 
participating programs. This project evaluated data that are collected for screening and 
diagnostic services provided to NBCCEDP-eligible women through many service delivery 
mechanisms. Primarily, care was delivered by participating physicians, clinics, and hospitals 
or through a combination of these providers and county health departments. Trained medical 
record abstractors collected data from sampled medical records. A computer-based tool was 
used to collect the information from the medical chart. Specific rules were developed for 
data abstraction to ensure consistency in the data-collection process. We selected 6 of the 
largest state programs for the study, which contributed greater than 30% of the MDE data 
for the relevant period to validate the largest proportion of the MDE data in the most 
efficient way. For the project, we targeted programs with larger screening volumes to ensure 
Eheman et al. Page 2









sufficient overall sample sizes without excessive burden on individual providers. After 
selecting the participating programs, we selected 181 unique providers from a list of 
participating NBCCEDP providers. We determined the record type by the screening test type 
(either mammogram or Papanicolaou [Pap] test), whether the screening test led to additional 
diagnostic follow-up, and whether the diagnostic follow-up led to a cancer diagnosis (Table 
1). In total, we sampled 5603 breast and cervical cancer screening records from the 6 state 
programs and included screenings that took place between late 1996 and the end of 2004. 
We selected the case records using a 2-stage, stratified, random sample design. We selected 
program providers at the first stage, selecting the largest providers with certainty. At the 
second stage, we stratified the program records of the selected providers into 6 types: 
normal, abnormal, or cancer screening outcomes for both mammography and Pap tests. To 
ensure sufficiently powered samples of all record types, we selected cancer screening 
outcomes with certainty. We assessed data quality by comparing screening, diagnostic, and 
final diagnosis data from the CDC MDE database with data obtained from the medical 
records.
Medical chart abstractions began in May 2004 and continued through July 2006. We 
abstracted all sampled records within each state over a period of 6 to 8 weeks. Medical 
records were located in various provider settings, including hospitals, local and state health 
departments, screening centers, and mobile facilities.
We developed a customized, laptop-based data abstraction tool for the collection of 76 
categorical variables and 11 text-based variables, which captured text from all diagnostic 
test reports and pathology reports. The variables selected for evaluation were those that were 
considered most relevant for assessing the quality and timeliness of program services. Text 
fields were added to collect the verbatim results of all medical tests, including the radiology 
and pathology reports of mammograms and biopsies, in addition to the information captured 
as categorical variables. Demographic variables collected included date of birth, race, and 
ethnicity.
Screening variables that were collected for breast cancer early detection included previous 
mammogram (yes or no) with date, symptoms (yes or no), clinical breast examination (CBE) 
performed and results (normal or abnormal), and screening mammogram result (Breast 
Imaging Reporting and Data System [BI-RADS] codes9: normal, benign, probably benign, 
suspicious abnormality, highly suggestive of malignancy, assessment incomplete). In the 
overall and outcome-specific concordance estimates for screening mammogram results, we 
excluded 686 records (23.2%) that did not have a code collected directly from the radiology 
report. These excluded reports primarily occurred before 1999, before the full adoption of 
BI-RADS coding by radiologists. Screening variables that were collected for cervical cancer 
early detection included previous Pap test (yes or no) with date and Pap result (1991 
Bethesda system categories10: normal, infection/reaction, atypical squamous cells [ASC] of 
unknown significance [ASCUS], low-grade squamous intraepithelial lesion, high-grade 
squamous intraepithelial lesion, or invasive squamous cell cancer; 2001 Bethesda system 
categories11 subdivided ASCUS into 2 categories: ASC of undetermined significance (ASC-
US) and ASC-cannot exclude high-grade intraepithelial lesions (ASC-H)).
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Diagnostic variables that were abstracted both for breast cancer and cervical cancer included 
the types of procedures performed, final diagnosis, and status of treatment. At least 10% of 
the NBCCEDP records were reabstracted by a second abstractor to monitor inter-rater 
reliability throughout the abstraction process, maintaining an average inter-rater reliability of 
95%.
Analysis Methods
MDE data were collected from 1996 through 2004. To compare results between the 
abstracted data, which we considered the “gold standard,” and the corresponding MDE data, 
we estimated 4 performance measures: abnormal mammogram screening and abnormal Pap 
test rates and breast and cervical cancer detection rates. These outcome-specific screening 
rates are routinely used in analyzing the MDEs.
We estimated overall concordance as the percentage agreement between the values of the 
corresponding abstracted and MDE variables. Because many of the outcomes are relatively 
rare, overall concordance has limited utility for assessing the MDE data quality. Therefore, 
to evaluate MDE data quality more thoroughly, we calculated outcome-specific concordance 
for each outcome level of the evaluated variables. For each outcome-specific concordance, 
we identify the abstracted records with the given outcome, then link these abstracted records 
to the corresponding MDE records. The outcome-specific concordance is defined as the 
percentage of these linked MDE records that also have the given outcome. For example, in 
the screening mammography results evaluation variable, we identify the abstracted records 
with a “normal” outcome (ie, no diagnostic follow-up) value and link these abstracted 
records to the corresponding MDE records. The outcome-specific concordance is the 
percentage of these linked MDE records that also indicates a “normal” mammography 
screening value. In the assessment of both overall and outcome-specific concordance, we 
excluded records with missing abstracted values because of archived or otherwise 
unavailable medical charts for the corresponding variable.
We report 95-percent confidence intervals (CIs) for both overall and outcome-specific 
concordance estimates. We weighted all concordance estimates to account for the 
differential sampling rates by screening record type and outcome. We adjusted the weights 
to account for providers who had either refused to participate or had closed and for missing 
or archived sample records that we could not replace and had to exclude from the project. To 
estimate the standard errors of all weighted concordance estimates appropriately, we used 
SUDAAN statistical software (RTI International, Research Triangle Park, NC) to account 
for the complex sample design.11
Results
We analyzed the data abstracted from 5603 medical charts for 1996 through 2004 and 
compared those data with the MDE data reported in the NBCCEDP. To assess whether the 
differences between the abstracted/true values and the MDE data values altered program 
outcome measures significantly, we estimated 4 outcome rates for the abstracted data and 
the MDE data (Table 2). There were no significant differences between the abstracted and 
MDE data in these performance measures.
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Demographic variables were analyzed to assess potential differences between abstracted and 
MDE data among patient-specific variables. These variables included date of birth and race 
and ethnicity (Table 3). Date of birth was recorded very accurately (97.9%). Race and 
ethnicity were often missing from the abstracted medical records and from a substantial 
proportion of reports in the MDE data. Despite missing race and ethnicity reports from 5.6% 
of all medical records in the data abstraction, there was a high overall concordance of 
available race and ethnicity data, indicating that a result entered into the MDEs for race and 
ethnicity was usually accurate. Among records with reported racial and ethnic data, 
concordance ranged from 98.4% among non-Hispanic whites to 82.4% among non-Hispanic 
Asians or Pacific Islanders. Conversely, much of the race and ethnicity discordance (288 
records) occurred among those records classified as undocumented in the abstraction.
Data items that were validated to assess the recording of medical procedures related to the 
screening examinations for both breast and cervical cancer are presented in Table 4. Overall 
concordance for whether a woman had had a previous mammogram was 92.8%. MDE data 
were more accurate for determining whether a woman did have a previous mammogram 
than whether she had not had a previous mammogram. Overall concordance of the MDE and 
abstracted data for the date of the previous mammogram was approximately 90%, whereas 
breast symptoms had an overall concordance of approximately 88%. Breast symptoms were 
noted in the medical chart about 33% of the time where the MDE data reported no 
symptoms. However, if abstraction verified that no symptoms were reported, then 
concordance of the MDE data was 97.1% (95% CI, 95.4%-98.2%). The overall concordance 
for whether or not a CBE was performed was 86.5% (95% CI, 72.3%-94%). However, if a 
CBE was identified from the medical record during abstraction, then, in almost all cases, the 
MDE data also indicated that a CBE had been done. The overall concordance for screening 
mammography result was 91.6% (95% CI, 87.6%-94.4%).
Whereas the concordance for diagnostic mammography was 97%, the accuracy of the MDEs 
in reporting whether a diagnostic mammogram was conducted was 70.2% (Table 5). The 
overall concordance rate for fine-needle aspiration (FNA) was high (99.6%), because the 
proportion of women who had an FNA was very low. The outcome-specific concordance for 
having an FNA was low at 58.2%. The concordance both for ultrasound and for breast 
biopsy was approximately 99%. Among cervical cancer diagnostic variables, the overall 
concordance for colposcopy with or without biopsy was very high (98.8% and 99.7%, 
respectively). However, the outcome-specific concordances for having had a colposcopy 
with or without biopsy were <65%.
The concordance for whether or not a woman had had a previous Pap test was about 80% 
(Table 4). The outcome-specific concordance for having had a previous Pap test was higher, 
at 88.3%. However, the accuracy of the MDEs in identifying whether a woman did not have 
a previous Pap test was far lower (69.7%). This indicates that the MDEs report a previous 
Pap in instances where the medical record did not provide evidence of a previous screening. 
The concordance for Pap test results was 89.9% (95% CI, 86.6%-92.5%).
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Participating programs in the NBCCEDP have collected and submitted to the CDC data 
from breast and cervical cancer screening and diagnostic services for over 4.5 million 
women screened. These data provide valuable information for monitoring and assessing 
program performance for the underserved women who are eligible for the program. 
Programs are required to conduct data management, quality-assurance, and evaluation 
activities. A CDC data management contractor provides technical assistance to programs, 
including software tools for data collection and validation, feedback reports, and systematic 
data-quality reviews conducted twice a year. Programs use these and other tools to identify 
invalid, incomplete, or unexpected variations within their local data systems and to produce 
provider feedback reports for assessment and data correction. Programs engage in other 
quality-assurance activities, including record audits, provider training on data reporting 
systems, and routine use of data for program monitoring. Although the program employs 
data-quality systems to monitor program services, a comprehensive evaluation of the 
validity of the national aggregate data at CDC has not been conducted previously. 
Consequently, the purpose of this project was to assess the correlation between data 
maintained in CDC's MDE database and patients' medical records.
There were protocol inconsistencies between the validation abstraction and the NBCCEDP 
in the capture of “other” race, multiple races, and missing race or ethnicity data. Validation 
protocols dictate that all data elements are abstracted as they appear in the medical records, 
such that abstracted race and ethnicity data were classified as undocumented if not reported 
on the medical record. In contrast, NBCCEDP administrative records were a valid source of 
these data for the MDEs.
We reviewed several other problematic variables to determine how data quality could be 
improved. The MDE data often did not report any breast symptoms although they were 
noted in the medical charts. During data abstraction, we determined that 1 program had not 
collected symptom information but assumed a result of “no symptoms.” On the basis of this 
finding, the CDC has directed all programs to report only information that is substantiated in 
the medical records.
Among the screening mammography variables, the outcome-specific concordance for 
“assessment incomplete” was lower than that for other mammography outcomes. This lower 
concordance is likely related to confusion about capturing the BI-RADS code when 
mammography is immediately followed by additional imaging studies. In many instances, 
additional imaging studies are performed on the same day as the initial mammogram, and 
the radiologist assigns a final BI-RADS code on the radiology report after additional tests 
are complete. The use of diagnostic mammography and ultrasound before assignment of a 
final BI-RADS code is more frequent in the United States than that reported in other 
countries.12 The common radiologist practice of recording only a final BI-RADS code 
contributes to the difficulty in capturing the results of more than 1 test conducted on the 
same day, noting that it was not uncommon for the final BI-RADS code to be reported as the 
screening mammography outcome. In this circumstance, according to MDE guidelines, 
providers are directed to code these mammograms as “assessment incomplete” and not 
Eheman et al. Page 6









reflect the final BI-RADS code of the diagnostic mammography. Assessing the complete 
diagnostic workup leading to the final imaging result for the women within the program is 
an important measure of service quality and cost. To reflect diagnostic workup more 
accurately in the MDE data, updates to the NBCCEDP protocols were made after this study 
to capture all diagnostic testing procedures and results.
The low concordance for certain Pap test results may be because of the change in the 
reporting system during the period from which the records were abstracted. The Bethesda 
system used for reporting specific Pap results changed in 2001, adding new categories 
(ASC-H) that were not part of the old system.13 Abstracted data included results from both 
the previous 1991 Bethesda system and the updated 2001 reporting system.
The outcome-specific concordance for undergoing a colposcopy with biopsy was <75%. 
Pathology reports were available for standard biopsies, endocervical curettage (ECC), or 
loop electrosurgical excision procedures. Confusion about what was truly considered a 
biopsy and whether the biopsy was done in conjunction with a colposcopy could explain the 
low outcome-specific concordance. ECC was a common procedure noted in the abstracted 
medical records, in which the final diagnosis was often determined based on the pathology 
reports associated with the ECC. If a standard cervical biopsy and an ECC were conducted 
at the same time, then the structure of the MDE data fields could not accommodate separate 
ECC and biopsy pathology report results. The recommendation to the program was to clarify 
what is meant by a cervical biopsy and to collect separate information about the occurrence 
and resulting pathology from an ECC. In 2009, the MDE was revised to report ECC, loop 
electrosurgical excision procedures, and cold knife conization as separate procedures in 
addition to colposcopy with biopsy.
To assess the validity of the MDE data, we assumed that the medical chart abstraction was 
the “gold standard.” Although this is a common assumption, there are limitations to this 
approach. There were instances in which the medical record did not clearly indicate what 
took place or specific information was missing. Because we excluded records with missing 
abstracted values from the concordance calculations, the extent of missing data also must be 
taken into consideration when using concordance measures to assess MDE data validity. 
Translating medical data into specific variable definitions is not always straightforward, so 
that different interpretations are sometimes possible for the same results. Protocol 
inconsistencies between the validation abstraction and the NBCCEDP in the capture of 
“other” race, multiple races, and missing race or ethnicity data resulted in conservative 
other/multiracial concordance estimates. In addition, because the program accessed 
administrative records to capture race or ethnicity data that may have been missing from the 
medical records, the undocumented outcome-specific concordance estimates are not 
meaningful.
In addition, records are archived based on individual program protocols or provider needs, 
so that the sampled records were not always available. Reports from providers of diagnostic 
services were not always available in the referral providers' charts. For example, if a woman 
had an abnormal screening test and was referred to a specialty provider for diagnostic 
follow-up, then there were instances in which the specialist's notes or consultation report 
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were missing from the referral provider's records. The absence of information from the 
medical chart could mean that either a test or procedure was not done or that data were 
missing from the medical chart. Also noteworthy is the possibility that the results may not 
be generalizable to lower volume providers, because the sampling frame excluded these 
providers to guarantee a sufficient sample of records.
Conclusions
Currently, as the only national cancer screening and early detection program in the United 
States, the NBCCEDP has screened over 4.5 million women. The NBCCEDP MDE 
database captures screening and diagnostic services data across a variety of clinic settings, 
containing a wealth of information regarding patterns of care, screening and follow-up, and 
outcome measures. Although the NBCCEDP employs data-quality systems to monitor 
program services, a comprehensive evaluation of the validity of the data had not been 
previously conducted. The purpose of this project was to assess the correlation between data 
maintained in the CDC's national MDE database and patient medical records. On the basis 
of the results from the analysis, a list of recommendations was developed to address issues 
that were identified for particular variable outcomes. Primarily, these recommendations 
focused on further clarification of variable definitions to improve the consistency of data 
collected from the various programs. These recommendations led to the following changes 
implemented in 2009 to the MDE reporting requirements for the national program: 1) report 
cancer stage from the cancer registry, 2) report the final imaging assessment, and 3) report 
more detailed information from the cervical biopsies. These reporting changes will improve 
the quality and completeness of the MDEs.
The overall conclusion from this comprehensive validation project of the NBCCEDP 
database is that, with few exceptions, the data collected from individual program sites and 
reported to CDC as MDEs are valid and consistent with sociodemographic and clinical data 
within medical records.
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Table 1
The Number of Abstracted Medical Records by Record Type: 1996 to 2004
Screening Procedure and Outcome No. of Abstracted Medical Records
Mammography screening
 No diagnostic follow-up 1076
 Diagnostic follow-up with no diagnosis of cancer 1069
 Diagnostic follow-up with a diagnosis of cancer 816
  Subtotal 2961
Pap test screening
 No diagnostic follow-up 1074
 Diagnostic follow-up with no diagnosis of cancer 887
 Diagnostic follow-up with a diagnosis of cancer 681
  Subtotal 2642
Total 5603
Abbreviations: Pap, Papanicolaou.
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Table 2
Outcome Performance Measures in Abstracted Data and Minimum Data Elements: 1996 
to 2004
Outcome and Data Source No. (%) 95% CI
Abnormal mammogram
 Abstracted 2242 (12.96) 10.35-16.12
 MDE 2961 (10.28) 9.63-10.97
Breast cancer detection
 Abstracted 2890 (0.57) 0.43-0.76
 MDE 2961 (0.60) 0.46-0.79
Abnormal Pap
 Abstracted 2636 (1.76) 1.53-2.03
 MDE 2642 (1.81) 1.62-2.02
CIN 2 or worse
 Abstracted 2599 (0.56) 0.45-0.69
 MDE 2642 (0.58) 0.47-0.71
Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; MDE, Minimum Data Elements; Pap, Papanicolaou.
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Table 3
Overall and Outcome-Specific Concordance for Demographic Variables: 1996 to 2004
Demographic Variable No. Concordance (95% CI)
Race/ethnicity 5603 90.7 (86.4-93.8)
 Non-Hispanic white 2444 98.4 (97.0-99.1)
 Non-Hispanic black 999 94.5 (90.0-97.0)
 Non-Hispanic Asian/Pacific Islander 75 82.4 (37.6-97.3)
 Non-Hispanic Alaskan Native/American Indian 175 85.3 (69.7-93.6)
 Hispanic 1538 97.0 (93.3-98.7)
 Other/multiraciala 58 66.1 (32.4-88.8)
 Undocumentedb 314 –c
Date of birth: Same date 5602 97.9 (96.9-98.5)
Abrbeviations: CI, confidence interval.
a
Protocol inconsistencies between the validation abstraction and the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in 
the capture of “other” race, multiple races, and missing race or ethnicity data resulted in conservative other/multiracial concordance estimates.
b
The validation project abstracted data strictly from program medical records, of which 5.6% were missing race and ethnicity reports. NBCCEDP 
accessed administrative records to capture race or ethnicity data for the Minimum Data Elements (MDEs). In total, 288 abstracted records were 
missing race and ethnicity but were reported in the MDEs. Notably, among the undocumented abstracted records, all of the discordance 
corresponds to single non-Hispanic race or Hispanic ethnicity reports in the MDEs.
c
The undocumented outcome-specific concordance estimates are not meaningful because of the inconsistent protocols between the validation 
project and the MDEs with respect to missing race and ethnicity reports. In addition, these suppressed estimates are unstable with relative standard 
errors that exceed 30%.
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Table 4
Overall and Outcome-Specific Concordance for Cancer Screening Variables: 1996 to 
2004
Screening Variable No. Concordance (95% CI)
Breast cancer screening variables
 Previous mammogram 2716 92.8 (89.4-95.2)
  Yes 2203 96.3 (94.1-97.7)
  No 444 85.6 (73.7-92.6)
  Month of previous mammogram 1726 88.3 (84.6-91.2)
  Year of previous mammogram 1964 90.7 (86.3-93.8)
 Breast symptoma 1962 87.9 (84.1-90.9)
  Yes 454 67.9 (55.8-78.0)
  No 1374 97.1 (95.4-98.2)
 Clinical breast examination performed 2961 86.5 (72.3-94.0)
  Yes 2657 97.3 (95.8-98.2)
  No/missing 304 23.4 (13.5-37.3)
 Clinical breast examination result 2813 84.5 (68.9-93.1)
  Normal 1906 99.5 (98.9-99.8)
  Abnormal 631 71.1 (59.9-80.2)
 Screening mammogram resultsb 2275 91.6 (87.6-94.4)
  Negative 509 97.4 (95.5-98.5)
  Benign 351 90.2 (81.6-95.0)
  Probably benign 57 87.6 (69.0-95.7)
  Suspicious abnormality 200 92.1 (84.9-96.0)
  Highly suggestive of malignancy 175 83.1 (67.1-92.2)
  Assessment incomplete 950 77.6 (62.6-87.7)
 Cervical cancer screening variables
 Previous Pap test 2642 81.0 (74.3-86.2)
  Yes 2237 88.3 (83.6-91.7)
  No 132 69.7 (46.2-86.1)
 Month of previous Pap test 1438 80.4 (74.7-85.0)
 Year of previous Pap test 1683 86.3 (82.1-89.6)
 Pap test results 2642 89.9 (86.6-92.5)
  Normal 799 97.8 (96.0-98.8)
  Infection/inflammation 251 66.5 (53.2-77.6)
  ASC-US 192 95.5 (85.4-98.7)
  LGSIL 721 94.6 (84.5-98.3)
  ASC-H 28
–
c
  HGSIL 472 94.5 (89.7-97.1)
  Cancer 32 98.5 (89.1-99.8)
  AGC 105 85.0 (71.2-92.9)
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Abbreviations: AGC, atypical glandular cells of undetermined significance; ASC-H, atypical squamous cells, cannot rule out a high-grade lesion; 
ASC-US, atypical squamous cells of undetermined significance; CI, confidence interval; HGSIL, high-grade squamous intraepithelial lesion; 
LGSIL, low-grade squamous intraepithelial lesion; Pap, Papanicolaou.
a
These exclude records from 1 state program that did not collect data on breast symptoms.
b
These exclude records in which Breast Imaging Reporting and Data System (BI-RADS) codes were not stated.
cSuppressed estimates are unstable with relative standard errors that exceed 30%.
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Table 5
Overall and Outcome-Specific Concordance for Cancer Diagnostic Variables: 1996 to 
2004
Diagnostic Variable No. Concordance (95% CI)
Breast cancer diagnostic variables
 Diagnostic mammogram performed 2961 97.0 (96.0-97.8)
  Yes 1092 70.2 (61.3-77.8)
  No/missing/unknown 1869 99.3 (98.8-99.6)
 Fine-needle aspiration 2961 99.6 (99.2-99.8)
  Yes 188 58.2 (40.2-74.2)
  No/missing/unknown 2773 99.86 (99.66-99.94)
 Repeat clinical breast examination and surgical consult 2961 94.5 (92.7-95.9)
  Yes 809 79.5 (67.9-87.7)
  No/missing/unknown 2152 95.1 (93.1-96.6)
 Breast ultrasound 2961 99.0 (98.5-99.3)
  Yes 999 91.0 (84.9-94.7)
  No/missing/unknown 2961 99.6 (98.5-99.3)
 Breast biopsy 2961 99.6 (99.3-99.7)
  Yes 924 90.5 (83.9-94.5)
  No/missing/unknown 2037 99.8 (99.6-99.9)
 Breast cancer diagnosis 2961 99.3 (98.9-99.5)
  Not diagnosed/refused/lost 2116 99.96 (99.93-99.98)
  Breast cancer 774 95.6 (84.5-98.9)
 Treatment for breast cancer started 774 87.6 (78.3-93.2)
Cervical cancer diagnostic variables
  Colposcopic biopsy 2,642 99.7 (99.3-99.9)
  Yes 96
–
a
 No/unknown 2,546 99.92 (99.81-99.96)
 Colposcopy with biopsy 2,642 98. 8 (97.3-99.4)
  Yes 1,242 64.4 (40.5-82.8)
 No/unknown 1,400 99.8 (99.5-99.9)
 Cervical cancer diagnosis 2,642 99.6 (99.2-99.8)
  Not cancer/undocumented 1,951 99.91 (99.86-99.94)
  CIN 2 or worse 648 86.8 (79.9-91.6)
 Treatment for cervical cancer started 648 86.5 (81.9-90.1)
Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia.
aSuppressed estimates are unstable with relative standard errors that exceed 30%.
Cancer. Author manuscript; available in PMC 2016 February 12.
